


PHARMACEUTICAL 2019

Avalo Therapeutics Inc. Rank 227 of 371







PHARMACEUTICAL 2019

Avalo Therapeutics Inc. Rank 227 of 371



The relative strengths and weaknesses of Avalo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avalo Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 198% points. The greatest weakness of Avalo Therapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 185% points.

The company's Economic Capital Ratio, given in the ranking table, is -233%, being 98% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	21,932
Cost of Goods Sold	7,478
Intangible Assets	47,651
Liabilities, Current	26,217
Liabilities, Non-Current	14,713
Other Assets	82
Other Compr. Net Income	0
Other Expenses	33,665
Other Liabilities	8,413
Other Net Income	-773
Property and Equipment	587
Research and Development	5,787
Revenues	18,327
Selling, General and Administrative Expense	10,677

Output Variable	Value in 1000 USD
Assets	70,251
Liabilities	49,343
Expenses	57,607
Stockholders Equity	20,908
Net Income	-40,053
Comprehensive Net Income	-40,053
Economic Capital Ratio	-233%